Track Oculis Holding AG Ordinary shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Oculis Holding AG Ordinary shares OCS · Stock Open Oculis Holding AG Ordinary shares in new tab

7.64 USD
EPS
-1.73
P/B
1.83
ROE
-47.49
Beta
0.29
Target Price
35.60 USD
Loading chart...
Key Metrics
Earnings dateMarch 2, 2027
EPS-1.73
Book Value4.17
Price to Book1.83
Debt/Equity1.34
% Insiders3.818%
Growth
Revenue Growth-0.97%
Estimates
Forward P/E-4.24
Forward EPS-1.80
Target Mean Price35.60

DCF valuation

Model fair value for Oculis Holding AG Ordinary shares (OCS)
Result
Sign in to run the valuation for OCS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 35.60 USD (low 19.39, high 41.05) · as of 14 Nov 2026
Low 19.39
Mean 35.60
High 41.05
Price 7.64
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Oculis Holding AG Ordinary shares Logo Oculis Holding AG Ordinary shares Analysis (OCS)

Switzerland Health Care Official Website Stock

Is Oculis Holding AG Ordinary shares a good investment? Oculis Holding AG Ordinary shares (OCS) is currently trading at 7.64 USD. Market analysts have a consensus price target of 35.60 USD. This suggests a potential upside from current levels.

Earnings Schedule: Oculis Holding AG Ordinary shares is expected to release its next earnings report on March 2, 2027. The market consensus estimate for Forward EPS is -1.80.

Investor FAQ

Does Oculis Holding AG Ordinary shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Oculis Holding AG Ordinary shares?

Oculis Holding AG Ordinary shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 2, 2027. The company currently has a trailing EPS of -1.73.

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Exchange Ticker
NMS (United States) OCS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion